Nagasaka, Misako

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 240

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

Nagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 219

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology

Cancer Genomics and DiagnosticsProtein Kinase Regulation and GTPase Signaling

Cited by 187

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 185

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Wang, H., Li, Z., Ou, Q., Wu, X., Nagasaka, M., Shao, Y., Ou, S. I., & Yang, Y. (2022) · Cancer Medicine

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 64

Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST

Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 63

Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.

Heist, R. S., Koyama, T., Murciano-Goroff, Y. R., Hollebecque, A., Cassier, P. A., Han, J.-Y., Tosi, D., Sacher, A. G., Burns, T. F., Spira, A. I., et al. (2024) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 48

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Murciano-Goroff, Y. R., Heist, R. S., Kuboki, Y., Koyama, T., Ammakkanavar, N. R., Hollebecque, A., Patnaik, A., Shimizu, T., Spira, A. I., Nagasaka, M., et al. (2023) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 40

Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

Tsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., et al. (2019) · Orphanet Journal of Rare Diseases

T-cell and Retrovirus StudiesPeripheral Neuropathies and Disorders

Cited by 33

TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors

Nagasaka, M., Ohe, Y., Zhou, C., Choi, C.-M., Yang, N., Liu, G., Felip, E., Pérol, M., Besse, B., Nieva, J., et al. (2023) · Future Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 32

Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)

Yamauchi, J., Tanabe, K., Sato, T., Nakagawa, M., Matsuura, E., Tsuboi, Y., Tamaki, K., Sakima, H., Ishihara, S., Ohta, Y., et al. (2022) · Viruses

T-cell and Retrovirus StudiesCervical and Thoracic Myelopathy

Cited by 31

Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Tamaki, K., Sato, T., Tsugawa, J., Fujioka, S., Yagishita, N., Araya, N., Yamauchi, J., Coler-Reilly, A. L. G., Nagasaka, M., Hasegawa, Y., et al. (2019) · Frontiers in Microbiology

T-cell and Retrovirus StudiesInfectious Diseases and Tuberculosis

Cited by 29

Trastuzumab Deruxtecan for ERBB2 -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials

Jänne, P. A., Planchard, D., Goto, K., Smit, E. F., de Langen, A. J., Goto, Y., Ninomiya, K., Kubo, T., Pérol, M., Felip, E., et al. (2025) · JAMA Network Open

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 27

ES28.04 Emerging Mechanisms to Target KRAS Directly

Nagasaka, M. (2021) · Journal of Thoracic Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 15

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 13

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations

Ahn, J., & Nagasaka, M. (2023) · Cancer Management and Research

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 12

MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study

Liu, G., Yang, N., Choi, C.-M., Ohe, Y., Sugawara, S., Yanagitani, N., De Braud, F., Nieva, J., Nagasaka, M., Zhou, C., et al. (2024) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 4